Escalation and de-escalation in HER2 positive early breast cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference48 articles.
1. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to;Cossetti;J Clin Oncol,2015
2. Trastuzumab containing regimens for early breast cancer;Moja;Cochrane Database Syst Rev,2012
3. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual;Giuliano;CA Cancer J Clin,2017
4. Herceptin Adjuvant (HERA) Trial Study Team, 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial;Cameron;Lancet,2017
5. Long-term follow-up of cardiac function and quality of life for patients in NSABP Protocol B-31/NRG Oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2;Ganz;J Clin Oncol,2017
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Trends in chemotherapy use for early-stage breast cancer from 2006 to 2019;Breast Cancer Research;2024-06-13
2. Addressing Breast Cancer Disparities in Advancements for Conquering Drug Resistance;Overcoming Breast Cancer Therapy Resistance;2024
3. Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer;Journal of Immunotherapy and Precision Oncology;2022-12-13
4. Impact of AJCC prognostic staging on prognosis and postmastectomy radiotherapy decision-making in hormone receptor-positive and HER2-positive breast cancer;BJS Open;2022-03-08
5. Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial;Clinical Breast Cancer;2021-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3